Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2018 from OUS - The Lipid Clinic

15 publications found

Dufour R, Hovingh GK, Guyton JR, Langslet G, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M (2018)
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial
J Clin Lipidol (in press)
DOI 10.1016/j.jacl.2018.11.007, PubMed 30591415

Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Guyton JR (2018)
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
Atherosclerosis, 278, 307-314
DOI 10.1016/j.atherosclerosis.2018.08.036, PubMed 30293878

Gaudet D, Langslet G, Gidding SS, Luirink IK, Ruzza A, Kurtz C, Lu C, Somaratne R, Raal FJ, Wiegman A (2018)
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
J Clin Lipidol, 12 (5), 1199-1207
DOI 10.1016/j.jacl.2018.05.007, PubMed 30318065

Holven KB, Narverud I, van Lennep JR, Versmissen J, Øyri LKL, Galema-Boers A, Langslet G, Ulven SM, Veierød MB, Retterstøl K, Bogsrud MP (2018)
Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH
J Clin Lipidol, 12 (3), 748-755.e2
DOI 10.1016/j.jacl.2018.02.021, PubMed 29609857

Hovingh GK, Guyton JR, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, Manvelian G, Farnier M (2018)
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia
J Clin Lipidol, 12 (6), 1463-1470
DOI 10.1016/j.jacl.2018.08.011, PubMed 30287210

Hovland A, Mundal LJ, Igland J, Veierød MB, Holven KB, Bogsrud MP, Tell GS, Leren TP, Retterstøl K (2018)
Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia
Stroke, STROKEAHA118023456 (in press)
DOI 10.1161/STROKEAHA.118.023456, PubMed 30580708

Korman MJ, Retterstøl K, Kristiansen IS, Wisløff T (2018)
Are PCSK9 Inhibitors Cost Effective?
Pharmacoeconomics, 36 (9), 1031-1041
DOI 10.1007/s40273-018-0671-0, PubMed 29777433

McCullough PA, Ballantyne CM, Sanganalmath SK, Langslet G, Baum SJ, Shah PK, Koren A, Mandel J, Davidson MH (2018)
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)
Am J Cardiol, 121 (8), 940-948
DOI 10.1016/j.amjcard.2017.12.040, PubMed 29472008

Mundal LJ, Igland J, Veierød MB, Holven KB, Ose L, Selmer RM, Wisloff T, Kristiansen IS, Tell GS, Leren TP, Retterstøl K (2018)
Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia
Heart, 104 (19), 1600-1607
DOI 10.1136/heartjnl-2017-312706, PubMed 29622598

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Heart Fail Rev, 23 (3), 303-323
DOI 10.1007/s10741-018-9685-0, PubMed 29516230

Retterstøl K, Svendsen M, Narverud I, Holven KB (2018)
Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: A randomized controlled study
Atherosclerosis, 279, 52-61
DOI 10.1016/j.atherosclerosis.2018.10.013, PubMed 30408717

Svendsen K, Henriksen HB, Østengen B, Jacobs DR, Telle-Hansen VH, Carlsen MH, Retterstøl K (2018)
Evaluation of a short Food Frequency Questionnaire to assess cardiovascular disease-related diet and lifestyle factors
Food Nutr Res, 62
DOI 10.29219/fnr.v62.1370, PubMed 29720928

Svendsen K, Telle-Hansen VH, Mørch-Reiersen LT, Garstad KW, Thyholt K, Granlund L, Henriksen HB, Gran JM, Jacobs DR, Retterstøl K (2018)
A randomized controlled trial in Norwegian pharmacies on effects of risk alert and advice in people with elevated cardiovascular risk
Prev Med Rep, 12, 79-86
DOI 10.1016/j.pmedr.2018.08.004, PubMed 30191097

Urke EB, Søbye S, Ellingvåg A, Langslet G, Retterstøl K, Wandel M (2018)
Familial hypercholesterolemia and young patients' thoughts on own condition and treatment
Patient Educ Couns (in press)
DOI 10.1016/j.pec.2018.12.025, PubMed 30606641

Øyri LKL, Hansson P, Bogsrud MP, Narverud I, Florholmen G, Leder L, Byfuglien MG, Veierød MB, Ulven SM, Holven KB (2018)
Delayed postprandial TAG peak after intake of SFA compared with PUFA in subjects with and without familial hypercholesterolaemia: a randomised controlled trial
Br J Nutr, 120 (5), 597
DOI 10.1017/S0007114518001769, PubMed 30047345

 
Page visits: 92103